| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | 333 LAKESIDE DRIVE, FOSTER CITY | Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson | 01 Dec 2025 | 0000882095 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XLO | Prefunded Warrants (right to buy) | Exercise of in-the-money or at-the-money derivative security | $9,999,916 | +13,335,000 | +57% | $0.7499 | 36,645,266 | 26 Nov 2025 | Common Stock | 13,335,000 | $0.000100 | Direct | F1, F2 |
| transaction | XLO | Series B Warrants (right to buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -13,335,000 | -100% | $0.000000 | 0 | 26 Nov 2025 | Common Stock | 13,335,000 | $0.7499 | Direct | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock"). |
| F2 | The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. |
| F3 | The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share. |
| F4 | The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025. |